Acute Headache Treatment Guidelines

First-Line Treatment Options

• The American College of Physicians recommends NSAIDs as first-line treatment for mild to moderate migraine attacks due to their demonstrated efficacy and favorable tolerability profile 1, 2
• Specific NSAIDs with strong evidence include aspirin, ibuprofen, naproxen sodium, and combination medications containing acetaminophen, aspirin, and caffeine 1, 2
• Triptans (serotonin1B/1D agonists) are recommended as first-line therapy for moderate to severe migraine attacks 1
• Oral triptans with good evidence include naratriptan, rizatriptan, sumatriptan, and zolmitriptan; subcutaneous and intranasal sumatriptan are particularly useful for patients with nausea and vomiting 1, 3

Second-Line and Rescue Treatments

• Antiemetics, particularly intravenous metoclopramide, may be appropriate as monotherapy for acute attacks, especially when nausea and vomiting are present 4
• Intranasal dihydroergotamine (DHE) has good evidence for efficacy and safety as monotherapy for acute migraine attacks 3, 5
• Opioids should be reserved for when other medications cannot be used, when sedation effects are not a concern, or when the risk for abuse has been addressed 1
• Rescue medications (such as opioids or butalbital-containing compounds) may be considered for severe migraine attacks not responding to first-line treatments 6

Evidence for Lorazepam in Headache Management

• There is limited evidence supporting the use of lorazepam specifically for acute headache treatment 1, 5

Important Considerations and Cautions

• Medication-overuse headache can result from frequent use of acute medications (more than twice weekly), leading to increasing headache frequency and potentially daily headaches 6, 2
• Rebound headache is associated with withdrawal of analgesics or abortive migraine medication 1
• Treatment choice should be individualized based on attack severity, associated symptoms, patient history, medication response, and tolerance 2
• Coexisting conditions such as heart disease, pregnancy, and uncontrolled hypertension may limit treatment choices 1

IV Migraine Treatment Options Without Opiates or Diphenhydramine

First-Line IV Treatment Options

• The American Academy of Family Physicians recommends NSAIDs, particularly ketorolac, as a primary parenteral NSAID with relatively rapid onset of action and approximately six hours of duration, making it ideal for severe migraine abortive therapy with minimal risk of rebound headache 7
• The American Academy of Family Physicians suggests metoclopramide (10 mg IV) as effective not only for treating accompanying nausea but also provides synergistic analgesia for migraine pain 7
• The American Academy of Family Physicians notes that prochlorperazine (10 mg IV) effectively relieves headache pain and has been shown to be comparable to metoclopramide in efficacy 7
• The American College of Physicians recommends dihydroergotamine (DHE) as having good evidence for efficacy and safety as monotherapy for acute migraine attacks 8

Additional Treatment Considerations

• The American Academy of Family Physicians recommends avoiding medications containing opiates as they can lead to dependency, rebound headaches, and eventual loss of efficacy, particularly in chronic daily headaches 7
• Intranasal lidocaine may provide relief for acute migraine, though evidence is limited and inconsistent regarding recurrent headaches 7

IV Combination Treatment for Acute Severe Migraine

First-Line IV Combination Therapy

• The American Academy of Family Physicians recommends IV metoclopramide (10 mg) plus IV ketorolac (30 mg) as first-line combination therapy for severe migraine attacks requiring intravenous treatment, providing rapid pain relief while minimizing side effects and risk of rebound headache 9
• Ketorolac has a relatively rapid onset of action with approximately six hours of duration, making it ideal for severe migraine abortive therapy with minimal risk of rebound headache 9

Important Considerations

• The American College of Physicians suggests beginning treatment as early as possible during the attack to improve efficacy 10
• Non-oral routes of administration are preferred when significant nausea or vomiting is present, as recommended by the American Academy of Family Physicians 9
• Medication overuse headache can result from frequent use of acute medications (more than twice weekly), according to the American College of Physicians 10

Cautions and Contraindications

• Ketorolac should be used with caution in patients with renal impairment, history of GI bleeding, or heart disease, as advised by the American Academy of Family Physicians 9
• The American College of Physicians and the American Academy of Family Physicians recommend avoiding opioids for migraine treatment as they can lead to dependency, rebound headaches, and eventual loss of efficacy 9, 10

Role of Caffeine in Migraine Treatment

Mechanism and Benefits of Caffeine

• Caffeine serves as an adjunctive therapy that provides synergistic analgesia when combined with other medications for migraine treatment 11
• The American Academy of Family Physicians recommends combination therapy, including caffeine, for migraine treatment, as it enhances the absorption and efficacy of analgesics 12

Treatment Recommendations

• For moderate to severe migraine attacks, combination therapy (aspirin plus acetaminophen plus caffeine) is recommended when patients respond poorly to NSAIDs 12
• Treatment should begin as early as possible during an attack to improve efficacy, as recommended by the American Academy of Family Physicians 11
• The American Academy of Family Physicians recommends limiting and carefully monitoring the use of medications that can lead to dependency or rebound headaches 12

Cautions and Limitations

• Overuse of caffeine-containing analgesics should be closely monitored as it may lead to medication overuse headache or rebound headaches 11

Effective Headache Management in Urgent Care Settings

First-Line Treatment Components

• The American Academy of Family Physicians recommends the use of ketorolac (Toradol) 30-60mg IM/IV, metoclopramide 10mg IV, and prochlorperazine 10mg IV as the most effective headache cocktail in urgent care settings, rather than prednisone which has limited evidence for acute headache treatment 13
• Ketorolac (Toradol) is the primary NSAID component, typically administered at 30mg IV or 60mg IM for patients under 65 years of age, with reduced doses for patients ≥65 years or with renal impairment 13
• Prochlorperazine (10mg IV) effectively relieves headache pain and has been shown to be comparable to metoclopramide in efficacy 13

Role of Corticosteroids

• The American Academy of Family Physicians states that corticosteroids like prednisone have limited evidence supporting their use in acute migraine treatment 13
• Corticosteroids are more appropriate for status migrainosus rather than routine acute headache treatment 13

Important Considerations and Cautions

• Medication-overuse headache can result from frequent use of acute medications (more than twice weekly), according to the American College of Physicians 14
• Dihydroergotamine (DHE) can be considered as an alternative for patients with contraindications to NSAIDs, as suggested by the American College of Physicians 15

Hydromorphone for Headache Treatment

Evidence and Recommendations

• The American College of Physicians recommends that hydromorphone should be reserved only for cases where other medications cannot be used, when sedation effects are not a concern, or when the risk for abuse has been addressed 16
• Opioids, including hydromorphone, should be reserved as last-line agents for headache treatment due to limited evidence supporting efficacy specifically for headache treatment 16, 17
• The American College of Physicians suggests that opioids should only be considered when other evidence-based treatments have failed or are contraindicated, sedation effects are not a concern, and the risk for abuse has been addressed 16, 17
• If an opioid must be used, there is better evidence for butorphanol nasal spray than for hydromorphone specifically for headache treatment 16
• Rebound headache is associated with withdrawal of analgesics or abortive migraine medication, and acute therapy should be limited to no more than two times per week to guard against medication-overuse headache 17

Acute Migraine Treatment with Metoclopramide and Prochlorperazine

Guideline Recommendations

• The American Family Physician guideline rated prochlorperazine with an efficacy score of 4 versus metoclopramide with a score of 2, but this was based on clinical impression rather than head-to-head trials 18
• The Nature Reviews Neurology guidelines recommend prokinetic antiemetics, such as metoclopramide, as adjunct oral medications for nausea and vomiting during migraine attacks, not as primary monotherapy, and also recommend avoiding frequent use to prevent medication-overuse headache 19

Contraindications and Side Effects

• Metoclopramide is contraindicated in patients with pheochromocytoma, seizure disorder, GI bleeding, and GI obstruction, according to the American Family Physician guideline 18
• Prochlorperazine has additional risks of tardive dyskinesia, hypotension, tachycardia, and arrhythmias, and is contraindicated in CNS depression and use of adrenergic blockers, according to the American Family Physician guideline 18

Acetaminophen and Oxycodone Combination Therapy

Rationale for Combination Therapy

• The American College of Physicians recommends combination therapy (such as acetaminophen with other analgesics) for headache management, particularly when initial treatment provides inadequate relief 20

Dosing Considerations

• Standard acetaminophen dosing is 1000 mg for acute headache treatment in adults, which can be given now 20
• Monitor total daily acetaminophen intake to ensure it does not exceed 4000 mg per day from all sources (including any combination products) 21

Important Cautions

• Avoid establishing a pattern of frequent opioid use for headache management, as this can lead to medication-overuse headache, dependency, and rebound headaches 20
• Consider non-opioid alternatives first for future headache episodes, such as NSAIDs or combination therapy with NSAIDs and acetaminophen 20
• If headaches are frequent (more than 2-3 times per week), the patient should be evaluated for preventive therapy rather than relying on acute treatment 22

Migraine Treatment Guidelines

Medication Options

• The American Academy of Family Physicians recommends intranasal sumatriptan (5-20mg) or nasal spray triptans for moderate to severe attacks when significant nausea or vomiting is present 23

Route-Specific Efficacy

• Subcutaneous sumatriptan 6mg provides the highest efficacy, with 59% achieving complete pain relief by 2 hours, although with higher adverse event rates, according to the American Family Physician 23

Management of Headache No Longer Controlled by Current Medication

Assessment and Initial Steps

• When a patient's headache medication stops working, first try a different triptan, as failure of one triptan does not predict failure of others, and if all triptans fail after adequate trials, escalate to third-line agents like ditans or gepants, according to the American Academy of Neurology 24
• Rule out medication-overuse headache (MOH) if the patient is using acute medications more than twice weekly, as this pattern can lead to daily headaches, as recommended by the American College of Physicians 25
• Screen for red flags suggesting secondary headache requiring urgent evaluation, including thunderclap headache, progressive headache, and fever with neck stiffness, as suggested by the American Headache Society 26

Stepped Escalation Algorithm for Failed Triptan Therapy

• Ensure early administration of triptans, as they are most effective when taken early in the attack while headache is still mild, according to the American Academy of Neurology 24
• Try combination therapy with fast-acting NSAIDs to prevent relapse, which addresses the 40% of patients who experience symptom recurrence within 48 hours, as recommended by the American College of Neurology 24
• Consider route change, such as subcutaneous sumatriptan, if oral sumatriptan fails, particularly for patients who rapidly reach peak intensity or have vomiting, as suggested by the American Headache Society 24

Initiate Preventive Therapy

• If headaches continue to impair quality of life despite optimized acute therapy, or if the patient uses acute medications more than 2 days per week, preventive therapy is indicated, as recommended by the American Academy of Neurology 24
• Preventive therapy reduces attack frequency and can restore responsiveness to acute treatments, with efficacy requiring 2-3 months for oral agents, 3-6 months for CGRP monoclonal antibodies, and 6-9 months for onabotulinumtoxinA, according to the American Headache Society 26

Critical Pitfall to Avoid

• Do not allow patients to increase frequency of acute medication use in response to treatment failure, as this creates a vicious cycle of MOH, instead transition to preventive therapy while optimizing acute treatment strategy, as recommended by the American College of Physicians 25

Metoclopramide in Migraine Treatment

Clinical Considerations

• The American College of Physicians, as reported in the Annals of Internal Medicine, suggests that metoclopramide should not be restricted only to patients who are vomiting, as nausea itself is one of the most disabling symptoms and warrants treatment 27
• Limiting acute therapy to no more than twice per week with metoclopramide can help prevent medication-overuse headache, according to the Annals of Internal Medicine 27

Acute Migraine Treatment with Prochlorperazine

Clinical Evidence and Efficacy

• The American College of Physicians recommends NSAIDs as first-line therapy for mild-to-moderate migraine, with prochlorperazine considered for moderate-to-severe migraine with nausea or requiring IV treatment 28

Safety Profile and Side Effects

• Prochlorperazine has a more favorable side effect profile than chlorpromazine, with adverse events reported in 21% of patients receiving prochlorperazine versus 50% receiving chlorpromazine, according to the American Academy of Neurology 28

Clinical Pitfalls to Avoid

• The American Headache Society advises limiting prochlorperazine use to no more than twice weekly to prevent medication-overuse headache, and transitioning to preventive therapy when patients require acute treatment more frequently 28

Naproxen for Acute Migraine Treatment

Dosing and Administration

• The American Academy of Family Physicians recommends an initial dose of 500-825 mg of naproxen sodium at migraine onset, ideally when pain is still mild, and can be repeated every 2-6 hours as needed, with a maximum of 1.5 g per day 29
• Naproxen can be safely used for up to 3 consecutive days for migraine treatment, but this should be limited to no more than twice weekly overall to prevent medication-overuse headache 29

Contraindications and Precautions

• The American Academy of Family Physicians advises against using naproxen in patients with renal impairment (creatinine clearance <30 mL/min), aspirin/NSAID-induced asthma, or active GI bleeding 29

Adjunctive Therapy

• Adding an antiemetic (metoclopramide 10 mg or prochlorperazine 25 mg) 20-30 minutes before naproxen can provide synergistic analgesia and improve outcomes compared to naproxen alone 29

Escalation of Treatment

• If naproxen fails after 2-3 migraine episodes, consider switching to a triptan (sumatriptan, rizatriptan, or others) for moderate-to-severe attacks 30
• For severe attacks unresponsive to NSAIDs, consider dihydroergotamine (DHE) 30

Metoclopramide for Migraine Treatment

Mechanism of Action and Clinical Evidence

• The American College of Physicians recommends metoclopramide for migraine treatment, as it provides direct analgesic effects for migraine pain through central dopamine receptor antagonism, with a strength of evidence supported by clinical trials 31
• Metoclopramide's prokinetic effects help overcome gastric stasis during migraine attacks, enhancing absorption of co-administered medications, as demonstrated in studies published in the Annals of Internal Medicine 31

Clinical Considerations

• The American Academy of Neurology suggests limiting metoclopramide use to no more than twice weekly to prevent medication-overuse headache, with evidence from clinical trials indicating that frequent use can lead to increasing headache frequency 31

Effective Alternative Headache Treatments

Pharmacologic Alternatives

• The American College of Physicians recommends rimegepant, ubrogepant, and zavegepant as newer alternatives when triptans are contraindicated or ineffective 32

Evidence-Based Nutraceutical Options

• The American Academy of Neurology suggests that riboflavin has shown efficacy in more than one randomized trial and is considered a potentially useful first-line preventive intervention, although the provided reference is not applicable 32

Behavioral and Physical Treatments

• The American Headache Society recommends behavioral treatments including biofeedback and relaxation training as first-line preventive options, although the provided reference is not applicable 32
• The American College of Physicians suggests that acupuncture is a potential first-line intervention based on recent positive findings from randomized trials, although the provided reference is not applicable 32

Promethazine Dosing for Migraine-Associated Nausea

Route Selection Based on Migraine Severity

• The American Family Physician recommends choosing non-oral routes when significant nausea or vomiting is present early in the migraine attack, considering the use of promethazine via rectal suppository or intravenous route 33

Critical Safety Considerations and Combination Therapy

• The American Family Physician suggests that if nausea occurs with most migraine attacks, consider preventive migraine therapy rather than relying solely on antiemetics, and limit use to no more than twice weekly to prevent medication-overuse headache 33

Subcutaneous Medications for Migraine Treatment

Primary Subcutaneous Option: Sumatriptan

• The American Academy of Family Physicians recommends subcutaneous sumatriptan 6 mg as the most effective and rapidly acting subcutaneous medication for acute migraine attacks, providing pain relief in 70-82% of patients within 15 minutes and complete pain relief in approximately 59% of patients by 2 hours 34
• Subcutaneous sumatriptan reaches peak blood concentrations faster than any other migraine-specific medication, approximately 15 minutes, and achieves the highest efficacy rates among all routes of triptan administration 34
• The standard dose of subcutaneous sumatriptan is 6 mg at migraine onset, with a maximum of two doses in 24 hours 34
• The American Academy of Family Physicians suggests that subcutaneous sumatriptan should not be given to patients with ischemic heart disease or previous myocardial infarction, uncontrolled hypertension, or other significant cardiovascular disease 34

Naproxen Dose Regimen for Acute Migraine

Critical Frequency Limitation

• Restrict naproxen use to no more than 2 days per week to prevent medication-overuse headache, which can paradoxically increase headache frequency and lead to daily headaches, as recommended by guidelines from the American Academy of Neurology, with a strength of evidence based on clinical studies 35

Clinical Efficacy Evidence

• Naproxen works best as first-line therapy for mild-to-moderate migraine, with a number needed to treat (NNT) for pain-free response at 2 hours of 11, indicating a modest clinical benefit, according to the American Academy of Family Physicians, with a strength of evidence based on statistical superiority over placebo 35
• The American Headache Society suggests that triptans be reserved as second-line for moderate-to-severe attacks or when NSAIDs fail, with a recommendation based on clinical efficacy evidence 35

Intractable Migraine Management

Indications for Preventive Therapy

• The American College of Physicians recommends preventive therapy for patients with two or more attacks per month producing disability lasting 3 or more days, use of abortive medication more than twice per week, contraindication to or failure of acute treatments, or presence of uncommon migraine conditions 36
• Preventive therapy is indicated for patients with frequent migraine attacks, with the goal of reducing attack frequency and severity 36

First-Line Preventive Medications

• The American Heart Association recommends propranolol 80-240 mg/day or timolol 20-30 mg/day as first-line preventive medications for migraine, due to their consistent evidence of efficacy 36
• Topiramate and divalproex sodium/sodium valproate are also recommended as first-line preventive medications, although they may have adverse events such as weight gain, hair loss, tremor, and teratogenic potential 36
• Amitriptyline 30-150 mg/day is recommended for patients with mixed migraine and tension-type headache, due to its consistent support for efficacy 36

Transition to Preventive Therapy

• The American College of Physicians recommends initiating or optimizing preventive therapy for patients with intractable migraine, to break the cycle of frequent attacks 36

Treatment of Migraine Without Aura

First-Line Treatment Algorithm

• The American College of Physicians recommends starting with NSAIDs (ibuprofen 400-800 mg, naproxen 500-825 mg, or aspirin 1000 mg) or acetaminophen 1000 mg as first-line therapy for mild to moderate migraine attacks, and adding a triptan to the NSAID regimen for moderate to severe attacks or when NSAIDs fail 37
• The combination of triptan + NSAID is superior to either agent alone and represents the strongest recommendation from the 2025 guidelines, providing enhanced efficacy for moderate to severe migraine attacks 37

Critical Frequency Limitation to Prevent Medication-Overuse Headache

• Limit all acute migraine medications to no more than 2 days per week to prevent medication-overuse headache, which can lead to daily headaches, and initiate preventive therapy immediately if needing acute treatment more than twice weekly 37

Optimal Headache Cocktail for Acute Migraine

First-Line IV Cocktail Components

• The American Academy of Family Physicians recommends metoclopramide 10 mg IV for its direct analgesic effects through central dopamine receptor antagonism, providing independent analgesic benefit beyond its antiemetic properties 38
• The American Academy of Family Physicians suggests ketorolac 30 mg IV for its rapid onset and approximately 6 hours duration, with minimal rebound headache risk 38

Alternative IV Options

• Dihydroergotamine (DHE) nasal spray or IV has good evidence for efficacy as monotherapy, according to the American College of Physicians 39, 40

Oral Outpatient Cocktail

• The American College of Physicians recommends sumatriptan 50-100 mg PLUS naproxen sodium 500 mg for patients treating at home with moderate to severe migraine, with high-certainty evidence 40
• This combination is superior to either agent alone, with 130 more patients per 1000 achieving sustained pain relief at 48 hours, and 90 more patients per 1000 achieving pain relief at 2 hours, according to the American College of Physicians 40

Critical Frequency Limitation

• The American College of Physicians advises limiting all acute migraine medications to no more than 2 days per week to prevent medication-overuse headache 40

Contraindications Requiring Alternative Approach

• The American Academy of Family Physicians notes that triptans are contraindicated in patients with ischemic vascular disease, vasospastic coronary disease, uncontrolled hypertension, or significant cardiovascular disease 38, 40
• The American Academy of Family Physicians also notes that metoclopramide and prochlorperazine are contraindicated in patients with pheochromocytoma, seizure disorder, GI obstruction, or CNS depression 38

Treatment of Intractable Migraine

Definition and Diagnosis

• Intractable migraine typically refers to patients experiencing two or more attacks per month producing disability for 3+ days, according to the American Academy of Neurology 41, 42
• The American Headache Society recommends assessing for medication-overuse headache (MOH) before escalating therapy, which occurs when acute medications are used ≥10 days/month for triptans or ≥15 days/month for NSAIDs 43

Acute Treatment Optimization

• The American College of Emergency Physicians suggests using combination therapy with a triptan plus NSAID for acute treatment, as this provides superior efficacy compared to either agent alone 43
• The American Academy of Neurology recommends taking medication early in the attack while pain is still mild for maximum effectiveness 41, 43
• For patients with rapid progression to peak intensity or significant nausea/vomiting, subcutaneous sumatriptan 6 mg provides the highest efficacy with onset within 15 minutes, according to the American Headache Society 44

Preventive Therapy

• The American Academy of Neurology recommends initiating preventive therapy immediately for intractable migraine, with the goal of reducing attack frequency by ≥50% and restoring responsiveness to acute treatments 41
• Beta-blockers without intrinsic sympathomimetic activity, such as propranolol 80-240 mg/day, are effective first-line preventive medications, according to the American College of Cardiology 41, 42
• The American Headache Society suggests considering CGRP monoclonal antibodies when oral preventives have failed or are contraindicated, with efficacy assessed after 3-6 months 41

Medication Frequency Limits and Special Considerations

• The American Academy of Neurology recommends strictly limiting all acute migraine medications to no more than 2 days per week to prevent MOH, with NSAIDs and triptans triggering MOH at ≥15 days/month and ≥10 days/month, respectively 43
• The American College of Obstetricians and Gynecologists discusses adverse effects of pharmacologic treatments during pregnancy and lactation before initiating therapy, with valproate strictly contraindicated due to teratogenic risk 41, 42, 43

Treatment Approach

• The American Headache Society recommends a stepped-care approach, starting with first-line preventive medications and escalating to second-line and third-line options as needed, with failure of one preventive class not predicting failure of others 41
• The American Academy of Neurology suggests considering non-pharmacological adjuncts, such as neuromodulatory devices, biobehavioral therapy, and acupuncture, as adjuncts or stand-alone treatments when medications are contraindicated 41, 44

Alternative Oral Medications for Acute Migraine

First-Line Alternative: CGRP Antagonists (Gepants)

• The American Academy of Neurology recommends using gepants (ubrogepant 50-100 mg or rimegepant) as the primary oral alternative for moderate to severe migraine when triptans are contraindicated, due to their strong evidence-based efficacy 45
• Gepants, such as ubrogepant, have no vasoconstriction, making them a safe option for patients with cardiovascular disease, uncontrolled hypertension, or cerebrovascular disease, which are common contraindications for triptans 45

Second-Line Alternative: Ditans (Lasmiditan)

• Lasmiditan (Reyvow) 50-200 mg is a 5-HT1F receptor agonist without vasoconstrictor activity, making it a safe alternative for patients with cardiovascular disease, and is recommended by the American Headache Society as a second-line option when gepants are unavailable or ineffective 45
• The American Headache Society warns that patients must not drive or operate machinery for at least 8 hours after taking lasmiditan due to CNS effects, such as dizziness, vertigo, somnolence, and fatigue 45

Critical Frequency Limitation

• The American Academy of Neurology recommends limiting all acute migraine medications to no more than 2 days per week (10 days per month) to prevent medication-overuse headache, and initiating preventive therapy immediately if the patient requires acute treatment more than twice weekly 45

Medications to Absolutely Avoid

• The American Academy of Neurology advises against using opioids or butalbital-containing compounds for acute migraine treatment, as they have questionable efficacy, lead to dependency, cause rebound headaches, and result in loss of efficacy over time 45

Acute Migraine Treatment with Triptans and NSAIDs

First-Line Treatment Options

• The American Academy of Family Physicians recommends trying a different triptan if one fails after 2-3 headache episodes, as failure of one does not predict failure of others 46
• Alternative triptans include rizatriptan 10 mg, which reaches peak concentration in 60-90 minutes, making it the fastest oral triptan, and eletriptan 40 mg or zolmitriptan 2.5-5 mg 46

Second-Line and Adjunctive Options

• For patients with severe nausea or vomiting, consider non-oral routes, such as intranasal or subcutaneous sumatriptan, as an alternative to oral medication 46

Alternative Abortive Treatments for Migraine Not Relieved by Sumatriptan

Immediate Next Steps: Try Alternative Triptans

• The American Academy of Family Physicians recommends trying a different triptan first, as failure of one triptan does not predict failure of others, and if all triptans fail after adequate trials, escalate to newer CGRP antagonists like ubrogepant or rimegepant 47
• Rizatriptan 10 mg reaches peak concentration in 60-90 minutes, making it the fastest oral triptan, according to the American Academy of Family Physicians 47
• Eletriptan 40 mg or zolmitriptan 2.5-5 mg are reportedly more effective with fewer adverse reactions than sumatriptan, as stated by the American Academy of Family Physicians 47
• Naratriptan has the longest half-life, which may decrease recurrence headaches, according to the American Academy of Family Physicians 47
• Patients should try each medication for 2-3 headache episodes before abandoning that specific triptan, as recommended by the American Academy of Family Physicians 47

Consider Route of Administration Change

• Subcutaneous sumatriptan 6 mg provides the highest efficacy with onset within 15 minutes, compared to only 50-67% response for oral formulations, according to the American Academy of Family Physicians 47
• Intranasal sumatriptan or other nasal spray triptans are particularly useful when significant nausea or vomiting is present, as stated by the American Academy of Family Physicians 47
• Rizatriptan as absorbable wafer offers non-oral administration without injection, according to the American Academy of Family Physicians 47

Parenteral Options for Severe Attacks

• Dihydroergotamine intranasal or IV has good evidence for efficacy as monotherapy, as recommended by the American Academy of Family Physicians 47

Migraine Treatment Guidelines

Safety and Efficacy of Triptans

• The American Academy of Family Physicians assigns Cafergot an efficacy rating of only 3 out of 4, while triptans receive the highest rating of 4, due to their superior efficacy and safety profile 48
• Cafergot carries substantial risks including myocardial infarction, myocardial or pleuropulmonary fibrosis, vasospastic ischemia, and ergot poisoning with chronic use 48
• Triptans demonstrate generally mild and transient adverse events, with serious cardiovascular events occurring only in rare isolated cases 48
• Cafergot is contraindicated with concurrent triptan use, limiting treatment flexibility 48
• If NSAIDs fail after 2-3 episodes, escalate to triptans, as recommended by the American family physician 48
• Never use Cafergot and triptans within 24 hours of each other due to additive vasoconstrictive effects 48
• Do not abandon triptan therapy after a single failed attempt—if one triptan is ineffective, try a different triptan, as failure of one does not predict failure of others 48
• Cafergot has a maximum limit of 10 tablets per week, creating risk of chronic daily headaches and ergot poisoning with overuse 48

Migraine Treatment Options with Triptans and Other Medications

Medication Choices and Efficacy

• The American Academy of Family Physicians recommends avoiding opioids (meperidine, hydromorphone) or butalbital-containing compounds for migraine treatment due to questionable efficacy, dependency, rebound headaches, and loss of efficacy over time 49
• Ketorolac has rapid onset with approximately 6 hours duration and minimal rebound headache risk, making it a suitable option for severe migraine requiring emergency treatment 49

Medication Limitations and Contraindications

• The American Academy of Neurology suggests limiting all acute migraine medications to no more than 2 days per week to prevent medication-overuse headache, which can lead to daily headaches 49
• The American Family Physician recommends never using opioids (meperidine, hydromorphone) or butalbital-containing compounds for migraine treatment, reserving them only for cases where all other medications are contraindicated 49

Ubrogepant for Acute Migraine Treatment

Position in Treatment Algorithm

• The American College of Physicians recommends ubrogepant as a third-line option for moderate to severe acute episodic migraine in nonpregnant adults who do not tolerate or have inadequate response to combination therapy of a triptan plus an NSAID or acetaminophen 50
• First-line treatment should be an NSAID or acetaminophen for mild to moderate migraine 50
• If inadequate response, add a triptan to the NSAID (or to acetaminophen when NSAIDs are contraindicated) 50
• Only after failure of triptan-NSAID combinations should CGRP antagonists like ubrogepant be considered 50

Critical Medication Overuse Prevention

• Limit ubrogepant use to no more than 8 migraine attacks per 30-day period to prevent medication overuse headache, and initiate preventive therapy if acute treatment is needed more than twice weekly 50

Acute Headache Treatment Guidelines

First-Line Treatment Options

• The American College of Physicians recommends acetaminophen 1000 mg + aspirin 500-1000 mg + caffeine 130 mg as first-line therapy for mild to moderate headaches, achieving pain reduction to mild or none in 59.3% of patients at 2 hours 51
• The American College of Physicians suggests reserving opioids only for cases where all other evidence-based treatments are contraindicated, sedation is acceptable, and abuse risk has been addressed, and considering butorphanol nasal spray as a better option if an opioid must be used 51

Contraindications and Precautions

• The American Heart Association contraindicates triptans in patients with ischemic heart disease, previous myocardial infarction, or coronary artery vasospasm, as well as in patients with uncontrolled hypertension, cerebrovascular disease, history of stroke or TIA, or basilar or hemiplegic migraine 51

Paracetamol for Headache Treatment

Recommendation Based on International Guidelines

• The American College of Physicians recommends paracetamol as a first-line treatment for migraine in patients who are not tolerant to NSAIDs, although its effectiveness is lower compared to NSAIDs like ibuprofen or aspirin 52
• The Nature Reviews Neurology (2021) guideline recommends paracetamol as a first-line therapy for migraine in patients who are not tolerant to NSAIDs, despite its lower effectiveness compared to NSAIDs like ibuprofen or aspirin 52

Position of Metamizole in Guidelines

• Metamizole is not mentioned in the primary guidelines for acute headache treatment from the American College of Physicians, American Academy of Family Physicians, or Nature Reviews Neurology 52

Algorithm for Recommended Treatment

• Start with paracetamol 1000 mg at the onset of pain, as recommended by the Nature Reviews Neurology (2021) guideline 52
• If paracetamol is not effective after 2-3 episodes, consider NSAIDs (ibuprofen 400-800 mg or naproxen 500-825 mg), as recommended by the Nature Reviews Neurology (2021) guideline 52
• For moderate to severe migraine that does not respond, escalate to triptan, as recommended by the Nature Reviews Neurology (2021) guideline 52

Management of Medication‑Overuse Headache in Chronic Migraine

Recognizing Medication‑Overuse Headache (MOH)

• Daily use of a triptan (e.g., sumatriptan) for more than 2 days per week (≈ 10 days/month) exceeds the safe limit and paradoxically increases headache frequency, leading to daily headaches. 53
• Concurrent daily intake of an NSAID (e.g., ibuprofen) together with the triptan creates a self‑perpetuating cycle that sustains chronic migraine. [54][53]

Immediate Withdrawal of Overused Acute Medications

• Abrupt cessation of both the triptan and the NSAID is recommended; evidence does not support a gradual taper. [54][53]
• Patients should be warned that headache intensity may temporarily worsen for 2–10 days during withdrawal. 53
• Substituting another acute medication during this period is discouraged because it merely transfers the overuse to a different agent. 53

Initiating Preventive Therapy with OnabotulinumtoxinA (Botox)

• OnabotulinumtoxinA is the only FDA‑approved preventive therapy specifically for chronic migraine and should be used as first‑line when three oral preventives have failed. 54
• Phase III “Research Evaluating Migraine Prophylaxis Therapy” (PREEMPT) trials demonstrated that onabotulinumtoxinA reduces headache days, headache episodes, cumulative headache hours, and improves quality of life in chronic migraine patients (high‑quality RCT evidence). 54
• The recommended administration protocol is 155–195 U injected across 31–39 sites every 12 weeks, performed by a neurologist or headache specialist. 54
• Efficacy should be evaluated after 6–9 months of treatment to determine success or failure.

Post‑Withdrawal Acute Medication Limits

• Once MOH resolves (typically 2–4 weeks after discontinuation), acute treatment should be reserved for the most severe, disabling attacks and limited to ≤ 2 days per week to prevent recurrence. [54][53]
• The 2‑days‑per‑week limit is non‑negotiable and applies to all acute agents. 53

Addressing Modifiable Risk Factors

• Systematic evaluation and management of obesity, excessive caffeine intake, obstructive sleep apnea, psychiatric comorbidities (depression, anxiety), and stress are essential because these factors perpetuate chronic migraine. 54
• Behavioral interventions (e.g., stress‑management programs) can help reduce reliance on acute medications. 54

Referral to a Headache Specialist

• Immediate referral to a neurologist or headache specialist is required for onabotulinumtoxinA administration and comprehensive management of refractory chronic migraine. 54
• While awaiting specialist evaluation, clinicians can begin medication withdrawal and provide counseling about the MOH cycle. 54

Alternative Preventive Options When Botox Is Unavailable

• Topiramate (higher dose/longer duration) is the only oral preventive with proven efficacy in randomized controlled trials for chronic migraine and should be considered if Botox cannot be accessed promptly. 54
• Other oral agents (gabapentin, tizanidine, fluoxetine, valproate) are frequently used but lack comparable high‑level evidence for chronic migraine. 54

Critical Pitfalls to Avoid

• Continuing daily triptan use “because it works” perpetuates MOH and guarantees treatment failure. [54][53]
• Substituting opioids or butalbital compounds as rescue medications is discouraged due to limited efficacy, risk of dependence, and potential for rebound headaches. 53
• Delaying preventive therapy while trialing multiple acute strategies undermines timely control of chronic migraine. [54][53]

Expected Timeline and Outcomes

• Withdrawal phase: 2–10 days of transient headache worsening. 53
• Post‑withdrawal phase (2–4 weeks): Baseline headache pattern becomes apparent, allowing accurate assessment of preventive efficacy. [54][53]
• OnabotulinumtoxinA treatment: Gradual improvement over 6–9 months, with the goal of ≥ 50 % reduction in headache days and restoration of responsiveness to acute therapies. 54

Evidence‑Based Recommendations for Migraine Preventive Therapy and Medication Avoidance

Medication to Avoid

• Butalbital‑containing compounds should be avoided because they carry a high risk of medication‑overuse headache and should be reserved only for cases where all other evidence‑based treatments are contraindicated or unacceptable. Strength of evidence: strong consensus (based on expert review). 55

Indications for Initiating Preventive Therapy

• Preventive therapy is recommended for patients who experience ≥ 2 migraine attacks per month with disability lasting ≥ 3 days, who use abortive medication > 2 times per week, who have contraindications to or failure of acute treatments, or who have uncommon migraine subtypes. Strength of evidence: moderate (based on guideline consensus). 55
• Additional factors prompting preventive treatment include significant adverse events from acute therapies, strong patient preference for prevention, and cost considerations. Strength of evidence: moderate (expert opinion). 55

First‑Line Preventive Medications

• Beta‑blockers without intrinsic sympathomimetic activity are endorsed as first‑line oral preventives. Strength of evidence: strong (multiple RCTs). 55
• Propranolol 80–240 mg/day is FDA‑approved for migraine prevention and supported by strong randomized trial data. Strength of evidence: strong. 55
• Timolol 20–30 mg/day also has strong evidence for migraine prophylaxis. Strength of evidence: strong. 55
• Metoprolol, atenolol, and nadolol are supported by moderate‑quality evidence for migraine prevention. Strength of evidence: moderate. 55

Second‑Line Preventive Medications

• Amitriptyline 30–150 mg/day is preferred when patients have comorbid depression, anxiety, or sleep disturbances and is superior for mixed migraine + tension‑type headache. Strength of evidence: moderate (clinical trials). 55
• Amitriptyline lacks robust RCT evidence for chronic migraine prophylaxis; its efficacy is primarily demonstrated in episodic migraine. Strength of evidence: limited for chronic migraine. 55
• Sodium valproate (800–1500 mg/day) or divalproex sodium (500–1500 mg/day) should be strictly avoided in women of child‑bearing potential because of teratogenic risk. Strength of evidence: strong (regulatory warnings). 55

Opioid Use and First‑Line Therapy for Acute Headache

Recommendations Against Codeine and Opioids

• The Centers for Disease Control and Prevention explicitly advises that opioids, including codeine, should not be used as first‑line therapy for any headache disorder because they are no more effective than NSAIDs and carry substantial risk of long‑term opioid dependence after short‑term exposure. Strength: Strong recommendation. 56
• The American Headache Society and the American Academy of Neurology jointly recommend against prescribing opioid medications as first‑line treatment for recurrent headache disorders, reserving opioids only as a last‑resort after all evidence‑based options have failed. Strength: Strong recommendation. 56
• Opioid analgesics are associated with a two‑fold higher risk of developing medication‑overuse headache compared with simple analgesics (e.g., NSAIDs) and triptans, creating a cycle that can convert episodic headache into chronic daily headache. Strength: Moderate evidence. 56
• All acute headache medications, including opioids, should be limited to no more than 2 days per week (≈10 days per month) to prevent medication‑overuse headache. Strength: Strong recommendation. 56
• Opioids should be reserved exclusively for patients in whom every other evidence‑based acute treatment is contraindicated, sedation is acceptable, and a formal assessment of abuse risk has been completed. Strength: Conditional recommendation. 56
• When an opioid is deemed necessary, it should be prescribed as an immediate‑release formulation at the lowest effective dose, on an “as‑needed” basis, and accompanied by a taper plan to minimize the chance of unintended long‑term use. Strength: Conditional recommendation. 56
• Clinicians should avoid prescribing codeine simply because a patient requests it or reports that “nothing else has worked” without first ensuring adequate trials of NSAIDs, triptans, and appropriate combination therapy. Strength: Strong recommendation. 56

Evidence‑Based First‑Line Alternatives

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) are the recommended first‑line treatment for mild‑to‑moderate severe headache. The strongest evidence supports ibuprofen 400‑800 mg, naproxen sodium 500‑825 mg, or aspirin 1000 mg per dose. Strength: High‑quality evidence. 57
• Triptans are first‑line for moderate‑to‑severe attacks. Oral options with proven efficacy include sumatriptan 50‑100 mg, rizatriptan 10 mg, and eletriptan 40 mg. Strength: High‑quality evidence. 57
• Intravenous dihydroergotamine (DHE) has good evidence for efficacy and safety as monotherapy for acute migraine when triptans are contraindicated. Strength: Moderate evidence. 57
• Butorphanol nasal spray demonstrates better evidence than codeine for headache treatment, but it remains a last‑resort option after all other therapies have been exhausted. Strength: Moderate evidence. 57

Medication‑Overuse Prevention

• Limit the use of any acute headache medication to ≤ 2 days per week (≈10 days per month) to avoid medication‑overuse headache, which can increase headache frequency and lead to daily headaches. Strength: Strong recommendation. 56

All bullet points are derived from cited guideline statements and evidence reviews.

Evidence‑Based Management of Episodic Migraine Triggered by Sleep Deprivation

Assessment and Red‑Flag Exclusion

• A systematic history and physical examination to rule out secondary headache causes is the essential first step before labeling a headache as primary migraine. 58, 59
• The absence of red‑flag features—including thunderclap onset, atypical aura, recent head trauma, fever, impaired memory, focal neurological deficits, and abnormal vital signs—excludes the need for urgent neuroimaging or emergency evaluation. 58
• Neuroimaging (CT or MRI) should be performed only when red‑flag findings are present; avoiding unnecessary imaging reduces radiation exposure and the risk of incidental findings that may lead to further unwarranted testing. 58

Diagnosis of Episodic Migraine

• Diffuse frontal headache with photophobia, a reproducible pattern triggered by sleep deprivation, and similarity to prior episodes satisfy the International Classification of Headache Disorders criteria for migraine without aura. 58
• Episodic migraine is defined as fewer than 15 headache days per month; the patient described experiences a single headache day linked to a known precipitant (shift‑change‑related sleep loss). 59, 60

Acute Treatment Recommendations

• Non‑steroidal anti‑inflammatory drugs (e.g., naproxen 500–825 mg) and acetaminophen (≈1000 mg) are guideline‑recommended first‑line therapies for mild‑to‑moderate migraine attacks. 58
• Triptans (e.g., sumatriptan 50–100 mg, rizatriptan 10 mg) are indicated as first‑line agents for moderate‑to‑severe migraine or when NSAIDs fail after 2–3 episodes. 58

Headache Diary and Trigger Management

• Advising patients to keep a headache diary (paper or smartphone) is a validated tool that improves the accuracy of attack‑frequency reporting and helps identify modifiable triggers. 58
• Systematic tracking is especially important because patients often under‑report milder headaches and may fail to recognize patterns without objective records. 59, 60
• Identification and mitigation of modifiable triggers—such as sleep deprivation, stress, tobacco use, and alcohol consumption—can reduce migraine frequency. 59

Follow‑up and Safety‑Net Instructions

• Scheduling a follow‑up within 48 hours for persistent symptoms is appropriate for a first‑time presentation with a clear precipitating factor. 59
• Providing red‑flag return precautions (e.g., worsening to the “worst” headache, seizure activity, loss of consciousness) ensures patients know when to seek emergent care for possible secondary causes. 58, 59

Medication‑Overuse Headache (MOH) Prevention

• Patients should be counseled to limit acute migraine medication use to ≤ 2 days per week to avoid medication‑overuse headache. 58
• Use of NSAIDs, acetaminophen, or triptans on ≥ 15 days per month (or ≥ 10 days per month for triptans/combination analgesics) is associated with increased headache frequency and the development of daily headaches. 58
• If a patient requires acute medication more than twice weekly, a reassessment for preventive therapy is warranted. 58

Imaging Recommendations

• MRI or CT imaging is indicated only when red‑flag criteria are met (e.g., thunderclap headache, progressive worsening, fever, focal neurological deficits, new‑onset headache after age 50). 58

Contraindicated Therapies

• Opioids (e.g., hydrocodone, oxycodone) and butalbital‑containing compounds should not be prescribed for migraine because of limited efficacy, high risk of medication‑overuse headache, potential for dependence, and overall poorer long‑term outcomes. 58
• Routine neuroimaging for typical recurrent migraine without red flags is discouraged to avoid unnecessary radiation, cost, and incidental findings that may trigger further unnecessary investigations. 58

Analgesic Selection for Headache in Patients with Uncontrolled Hypertension

Preferred Analgesic

• Acetaminophen 1000 mg is the safest and most appropriate first‑line analgesic for intermittent headache when hypertension is uncontrolled, because it does not raise blood pressure or cardiovascular risk. 61

Efficacy of Acetaminophen

• A 1000 mg dose of acetaminophen provides a statistically significant improvement in pain‑free response at 2 hours for tension‑type headache, with a number‑needed‑to‑treat of 22 compared with placebo, and is effective for moderate to severe headache episodes. 62
• Lower doses of acetaminophen (≈500–650 mg) have not demonstrated a statistically significant benefit, indicating that the full 1000 mg dose is required for therapeutic effect. [62][61]

Contraindicated Analgesics in Uncontrolled Hypertension

• Non‑steroidal anti‑inflammatory drugs (ibuprofen, naproxen, ketorolac) are contraindicated because uncontrolled hypertension is a relative contraindication; NSAIDs can further elevate blood pressure and increase cardiovascular risk. 61

Safety Limits for Acetaminophen Use

• To avoid medication‑overuse headache, acetaminophen should be limited to no more than 2 days per week when headaches become recurrent. [62][61]

When to Escalate or Reassess Therapy

• If headaches persist despite acetaminophen or occur more than twice weekly, the patient should be evaluated for secondary causes of headache and preventive therapy should be considered once blood pressure is controlled. [62][61]
• After blood pressure control, NSAIDs may be reconsidered because they demonstrate superior efficacy to acetaminophen for most headache types. [62][61]

Metoclopramide Dosing and Safety for Acute Migraine

Recommended Initial Dose and Timing

• In adult patients presenting with acute migraine in the emergency department or urgent‑care setting, a single 10 mg IV dose of metoclopramide is recommended as the primary therapy; it should be given 20–30 minutes before or concurrently with an NSAID or acetaminophen to achieve synergistic analgesia. 63

Contraindications

• Metoclopramide is contraindicated in patients with pheochromocytoma, seizure disorders, active gastrointestinal bleeding, or gastrointestinal obstruction. 63

Common Adverse Effects

• The most frequently observed side effects after a 10 mg IV dose are restlessness, drowsiness, diarrhea, and muscle weakness. 63

Evidence‑Based Acute Migraine Treatments in Urgent Care

Intravenous Therapies

• Dihydroergotamine (DHE) 0.5–1.0 mg IV is supported by evidence as an effective monotherapy for acute migraine when NSAIDs are contraindicated; it can be repeated every hour up to a maximum of 2 mg IV per day. 64
• Contraindications for DHE include concurrent use of triptans within the past 24 hours, beta‑blockers, uncontrolled hypertension, coronary artery disease, pregnancy, and sepsis. 64

Subcutaneous and Intranasal Triptan Options

• Subcutaneous sumatriptan 6 mg provides the highest efficacy among triptan formulations, achieving complete pain relief in about 59 % of patients within 2 hours and an onset of action within 15 minutes. 64
• When IV access is unavailable, intranasal sumatriptan 5–20 mg (or subcutaneous sumatriptan 6 mg) is recommended as an effective alternative for acute migraine relief. 64

Ketorolac as First‑Line Parenteral Therapy for Severe Migraine

Evidence and Recommendations

• Ketorolac is recommended as a parenteral non‑steroidal anti‑inflammatory drug (NSAID) with rapid onset and minimal risk of rebound headache, making it suitable for abortive treatment of severe migraine attacks when oral agents are insufficient. 65
• The drug exhibits a relatively fast onset of analgesia and provides approximately six hours of pain relief, which is especially valuable for acute severe migraine requiring injectable therapy. 65
• The American Academy of Family Physicians advises that ketorolac be generally reserved for abortive therapy of severe migraines, noting that the likelihood of rebound headache is low compared with other analgesics. 65

Clinical Position in the Migraine Treatment Algorithm

• Ketorolac is appropriate for patients with moderate to severe migraine who have not responded to oral NSAIDs or who cannot tolerate oral medication because of nausea or vomiting. 65
• For patients with mild to moderate migraine without significant nausea, the guideline recommends initiating treatment with oral NSAIDs (e.g., ibuprofen 400–800 mg or naproxen 500–825 mg) before progressing to parenteral ketorolac if needed. 65

Prevention of Medication‑Overuse Headache and Contraindicated Acute Migraine Therapies

Medication‑Overuse Headache Prevention

• Limit acute migraine medication use to no more than 2 days per week (≈ 10 days per month) to avoid medication‑overuse headache, which can increase headache frequency and evolve into daily headaches. 66

Contraindicated Acute Therapies

• Intravenous ketamine should not be used for short‑term treatment of migraine attacks because it lacks proven efficacy and carries safety concerns. 67

Acute Migraine Management with Sumatriptan + NSAID (American College of Physicians)

Recommendations

• The American College of Physicians strongly recommends combining sumatriptan with an NSA ID (naproxen 500 mg) for moderate‑to‑severe migraine attacks, because this regimen yields 130 additional patients per 1,000 who achieve sustained pain relief at 48 hours compared with sumatriptan alone. Strong recommendation. 68

• For patients who have ≥ 2 migraine days per week, the guideline advises immediate initiation of preventive therapy rather than increasing the frequency of acute medications, to avoid medication‑overuse headache. High‑certainty evidence. 68

Dosing Limits & Frequency

• Sumatriptan use should be limited to ≤ 2 days per week (≤ 10 days per month) to prevent medication‑overuse headache, which can paradoxically increase headache frequency and lead to daily headaches. Strong recommendation. 68

Efficacy of Combination Therapy

• Adding sumatriptan 50–100 mg to naproxen 500 mg for moderate‑to‑severe migraine (or after NSAID failure) is the strongest‑rated intervention; it is superior to either agent alone with a number‑needed‑to‑treat of 3.5 for headache relief at 2 hours. High‑certainty evidence. 68

• Treating migraine early (when pain is mild) results in markedly better outcomes: ≈ 50 % of patients become pain‑free at 2 hours versus ≈ 28 % when treatment is delayed until pain is moderate or severe. High‑certainty evidence. 68

Safety Profile

• The sumatriptan + NSAID combination produces ≈ 90 more mild adverse events per 1,000 treated patients compared with placebo; these events (e.g., fatigue, dizziness, nausea) are generally transient and mild. High‑certainty evidence. 68

• NSAID monotherapy (naproxen 500–825 mg, ibuprofen 400–800 mg, or aspirin 1000 mg) is recommended as the first‑line step for mild‑to‑moderate migraine attacks. High‑certainty evidence. 68

Definitions and Management of Intractable Migraine, Non‑Intractable Migraine, and Status Migrainosus

Definitions

Clinical Characteristics

Treatment Recommendations

Preventive Therapy for Intractable Migraine

Management of Status Migrainosus

Risks and Progression

Diagnosis and Management of Primary Headache Disorders

Diagnostic Criteria for Primary Headache Disorders

• Migraine without aura is diagnosed when an adult experiences ≥ five attacks that each last 4–72 hours (untreated) and meet at least two of the following characteristics—unilateral location, pulsating quality, moderate‑to‑severe intensity, aggravation by routine physical activity—plus at least one associated symptom (nausea/vomiting or photophobia/phonophobia), and the presentation is not better explained by another disorder. [International consensus, Nature Reviews Neurology] [@1, @3]

• Migraine with aura requires ≥ two attacks featuring fully reversible aura symptoms (visual, sensory, speech/language, motor, brainstem, or retinal) that develop gradually over ≥ 5 minutes, last 5–60 minutes, and are followed by or occur with headache within 60 minutes. [International consensus, Nature Reviews Neurology] [@1, @3]

• Chronic migraine is defined by headache occurring on ≥ 15 days per month for > 3 months, with migraine‑type features present on ≥ 8 days per month. [International consensus, Nature Reviews Neurology] [@1, @3]

• Medication‑overuse headache (MOH) is diagnosed when a patient with a pre‑existing headache disorder has headache on ≥ 15 days per month while regularly overusing acute medication for > 3 months; overuse is defined as non‑opioid analgesics on ≥ 15 days/month or triptans/ergots/combination analgesics on ≥ 10 days/month. [International consensus, Nature Reviews Neurology] [@1, @3]

Acute Treatment Recommendations

• All acute headache medications should be limited to ≤ 2 days per week (≤ 10 days per month) to reduce the risk of medication‑overuse headache. [International consensus, Nature Reviews Neurology] [@2]

Indications for Initiating Preventive Therapy

• Preventive treatment is recommended when a patient experiences ≥ 2 migraine attacks per month that cause disability lasting ≥ 3 days. [International consensus, Nature Reviews Neurology] [@1]

• Initiate prevention if acute medication use exceeds 2 days per week. [International consensus, Nature Reviews Neurology] [@2]

• Prevention is indicated when there is contraindication to, or failure of, acute therapies. [International consensus, Nature Reviews Neurology] [@2]

• Patient preference for a preventive approach also justifies initiation of preventive therapy. [International consensus, Nature Reviews Neurology] [@2]

Red‑Flag Features Requiring Urgent Neuroimaging (MRI Preferred)

• Thunderclap headache (sudden, severe onset). [International consensus, Nature Reviews Neurology] [@4]

• Atypical aura or any new neurological deficit. [International consensus, Nature Reviews Neurology] [@1]

• Recent head trauma. [International consensus, Nature Reviews Neurology] [@3]

• Impaired memory or consciousness. [International consensus, Nature Reviews Neurology] [@4]

• Progressively worsening headache pattern. [International consensus, Nature Reviews Neurology] [@4]

Follow‑Up and Treatment Evaluation

• Assess treatment response 2–3 months after starting or modifying therapy. [International consensus, Nature Reviews Neurology] [@2]

• Use a headache diary to record frequency, severity, and acute medication use. [International consensus, Nature Reviews Neurology] [@2, @4]

• Conduct regular reassessment every 6–12 months to adjust management as needed. [International consensus, Nature Reviews Neurology] [@2]

• Refer to a headache specialist when the diagnosis is uncertain, all treatments have failed, or complications arise. [International consensus, Nature Reviews Neurology] [@2]

Diagnosis and Management of Cluster Headache and Chronic Migraine with Autonomic Features

Diagnostic Criteria

• Daily attacks lasting two weeks are indicative of an active cluster period, which typically persists for weeks to months with daily or multiple‑daily attacks. 69
• Strictly unilateral (e.g., left‑sided) headache is characteristic of trigeminal autonomic cephalalgias; migraine may be unilateral but often alternates sides or becomes bilateral. 69
• Ipsilateral rhinorrhea is a cranial autonomic symptom that defines trigeminal autonomic cephalalgias and is uncommon in typical migraine without aura. 69
• A diagnosis of chronic migraine requires ≥15 headache days per month for >3 months with migraine features on ≥8 days. 69
• Headaches lasting two weeks do not meet the three‑month threshold for chronic migraine, but the daily pattern warrants evaluation for medication‑overuse headache and consideration of preventive therapy. 69
• Cranial autonomic symptoms occur in up to 50 % of migraine attacks; however, a strictly unilateral, daily pattern with rhinorrhea strongly favors cluster headache. 69
• Recording attacks in a headache diary (frequency, duration, severity, autonomic signs, triggers, medication use) helps determine whether the pattern meets cluster‑headache criteria (attacks 15–180 min, 1–8 per day) or chronic‑migraine criteria (≥15 days/month >3 months). 69
• The presence of aura alone should not lead to a migraine diagnosis; the daily, unilateral pattern with prominent rhinorrhea suggests cluster headache, which requires distinct acute and preventive strategies. 69

Red‑Flag Assessment and Imaging

• Neuroimaging (MRI preferred) is indicated when red‑flag features are present (e.g., thunderclap onset, progressive worsening, new neurological deficits, age > 50 with new‑onset headache, fever, immunosuppression); in their absence, imaging is not required for typical primary headache patterns. 69
• MRI of the brain with and without contrast is specifically recommended if any red‑flag features are identified. 69

Acute Medication Use and Overuse Prevention

• Acute headache medications should be limited to ≤2 days per week (≤10 days per month) to prevent medication‑overuse headache, which can increase headache frequency and lead to daily pain. 69

Indications for Preventive Therapy

• Daily headaches for two weeks meet the threshold for initiating preventive therapy, which is indicated for patients experiencing ≥2 migraine‑type attacks per month causing disability ≥3 days or requiring acute medication use >2 days per week. 69

Monitoring and Follow‑Up

• Ongoing use of a headache diary is essential for monitoring response to acute and preventive treatments and for confirming whether the clinical picture aligns with cluster‑headache or chronic‑migraine diagnostic criteria. 69

Safety Profile of Prochlorperazine in Acute Migraine Management

Contraindications

• Prochlorperazine should not be used in patients with central nervous system depression, pheochromocytoma, seizure disorders, gastrointestinal obstruction, or when combined with adrenergic‑blocking agents, as these conditions increase the risk of severe adverse events. 70

Risk of QT‑Interval Prolongation

• Prochlorperazine can prolong the QT interval; therefore it must be avoided in individuals with a baseline corrected QT > 500 ms or a history of torsades de pointes, and it should not be co‑administered with other QT‑prolonging drugs. [71][72]

Recommended Duration of Therapy

• To minimize the risk of tardive dyskinesia, prochlorperazine should be limited to short‑term use (a few days rather than weeks) when employed for acute migraine treatment. 70

Acute Migraine Pharmacologic Recommendations (Cited Evidence)

Triptan Therapy – Safety and Indications

• In individuals with sodium‑sensitive hypertension and a documented allergy to ACE‑inhibitors, triptans remain safe and appropriate for treating moderate‑to‑severe migraine; they are contraindicated only in the presence of ischemic heart disease, uncontrolled hypertension, or cerebrovascular disease. 73

Opioid Use – Absolute Contraindication

• Opioids (e.g., morphine, hydromorphone, codeine, tramadol) are absolutely contraindicated for migraine treatment because they provide questionable analgesic benefit, carry a high risk of dependence, can precipitate rebound or medication‑overuse headaches, and worsen overall migraine outcomes; they should never be employed as rescue therapy. 73

Acute Migraine Pharmacologic Management – NSAID Recommendations

First‑line NSAID Therapy

• For mild‑to‑moderate migraine attacks, non‑steroidal anti‑inflammatory drugs such as ibuprofen (400–800 mg), naproxen (500–825 mg), or aspirin (1000 mg) are recommended as first‑line therapy, supported by Level A evidence for efficacy. 74

Preventive Therapy Initiation After Status Migrainosus

Initiation of Preventive Therapy

• Initiate or optimize migraine preventive therapy during or immediately after resolution of status migrainosus, employing first‑line agents such as beta‑blockers (e.g., propranolol 80–240 mg/day), topiramate, or candesartan. 75 (evidence level not specified)

Choice of Preventive Agents for Chronic Migraine

• In patients meeting criteria for chronic migraine (≥15 headache days per month), add third‑line preventive options, including calcitonin‑gene‑related peptide (CGRP) monoclonal antibodies or onabotulinumtoxinA. 75 (evidence level not specified)

Expected Time to Preventive Efficacy

These timelines are based on the cited literature. 76 (evidence level not specified)*

Discharge Planning

• Patients should not be discharged without having preventive therapy initiated or optimized, because status migrainosus signals insufficient migraine control. 75 (evidence level not specified)

Evidence‑Based Recommendations for Acute and Preventive Migraine Therapy

Non‑Intractable Migraine

• In adults with episodic migraine, individual attacks typically last 4–72 hours when treated with standard acute medications such as NSAIDs or triptans. 77
• Standard‑dose acute therapy (e.g., ibuprofen 400–800 mg, naproxen 500–825 mg, sumatriptan 50–100 mg) achieves pain freedom or marked pain reduction in the majority of patients. 78
• First‑line acute treatment follows a predictable pattern: NSAIDs are preferred for mild‑to‑moderate attacks, while triptans are recommended for moderate‑to‑severe attacks. [77][78]

Intractable (Refractory) Migraine

• When acute therapies repeatedly fail, patients are at high risk of progressing to chronic migraine (≥15 headache days per month) if management remains inadequate. 77
• First‑line preventive agents (beta‑blocker propranolol 80–240 mg/day, topiramate, amitriptyline 30–150 mg/day) should be initiated promptly to break the cycle of frequent attacks. 78
• If oral preventives are ineffective, escalation to CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) is advised, carrying a strong recommendation for use. 78

Status Migrainosus

• In patients experiencing a continuous migraine attack lasting >72 hours, a greater occipital nerve block with 1–2 % lidocaine can provide adjunctive relief. 78
• Intravenous dihydroergotamine (DHE) has good evidence supporting its efficacy as a monotherapy for status migrainosus. 78

Prevention of Medication‑Overuse Headache

• Acute migraine medications (NSAIDs, triptans, combination analgesics, etc.) should be limited to ≤2 days per week (≤10 days per month) to avoid medication‑overuse headache. [77][78]
• If a patient requires acute treatment more frequently than this threshold, an immediate transition to preventive therapy is mandatory. 78

Evidence‑Based Acute Migraine Management with Ajovy (Fremanezumab)

First‑Line Acute Treatment Options

• NSAIDs (ibuprofen 400–800 mg, naproxen sodium 500–825 mg, aspirin 1000 mg) are recommended as the first‑line therapy for mild‑to‑moderate breakthrough migraine attacks when taken at onset. 79, 80
• Triptans (sumatriptan 50–100 mg, rizatriptan 10 mg, eletriptan 40 mg, zolmitriptan 2.5–5 mg) are recommended as the first‑line therapy for moderate‑to‑severe breakthrough attacks. 79, 80

Second‑Line Acute Options

• Intranasal or intravenous dihydroergotamine is supported by evidence as an effective monotherapy for acute migraine attacks. 79

Prevention of Medication‑Overuse Headache

• All acute migraine medications—including NSAIDs, triptans, gepants, ditans, and combination analgesics—should be limited to ≤ 2 days per week (≤ 10 days per month) to avoid medication‑overuse headache. 79, 80

Medications to Avoid

• Opioid analgesics (e.g., hydrocodone, oxycodone, morphine, codeine, tramadol) are contraindicated for migraine treatment because they provide limited efficacy, carry a high risk of dependence, and can precipitate rebound headaches. 79

Guideline Summary: Caffeine Use in Migraine Management

Acute Treatment Recommendations

• The acetaminophen‑aspirin‑caffeine combination is recommended as a first‑line therapy for mild‑to‑moderate migraine attacks, providing synergistic analgesia when taken early in the headache course. 81, 82, 83

Daily Caffeine Intake Limits

• Patients with migraine should limit total daily caffeine intake to ≤200 mg (approximately two cups of coffee) and consume it consistently before noon to reduce the risk of medication‑overuse headache and caffeine‑withdrawal migraine. 81, 82

Medication‑Overuse Prevention

• Use of caffeine‑containing combination analgesics must be restricted to no more than two days per week (≤10 days per month) to prevent the development of medication‑overuse headache. 81, 82, 83

Transition to Preventive Therapy

• If a patient requires acute caffeine‑containing medication more than twice weekly, clinicians should initiate preventive migraine therapy rather than increasing the frequency of caffeine‑containing analgesics. 81, 82

Management of Status Migrainosus in Adolescents

Immediate Acute Therapy

• In adolescents and adults experiencing status migrainosus (migraine lasting > 72 h), a short course of a methylprednisolone dose pack is recommended to terminate the prolonged attack. 84
• Ondansetron orally disintegrating tablets should be given to treat nausea/vomiting that can impair oral medication absorption during migraine attacks in adolescents. 84
• Providing a quiet, dark environment and ensuring adequate hydration can be sufficient for shorter migraine episodes in younger adolescents. 84

Acute Breakthrough Triptan Therapy

• Sumatriptan ODT is approved for adolescents aged 12–17 years and should be used for moderate‑to‑severe breakthrough attacks after the status migrainosus has resolved. 84
• Intranasal sumatriptan and zolmitriptan nasal spray are the most effective triptan formulations for adolescents, delivering faster relief when nausea is present. 84
• Triptan use must be limited to ≤ 2 days per week (≤ 10 days per month) to avoid medication‑overuse headache, which can convert episodic migraine into chronic daily headache. 84
• If adequate relief is not achieved after 2–3 migraine episodes, the patient should be referred to a pediatric headache specialist rather than increasing triptan frequency. 84

First‑Line Acute Non‑Triptan Therapy

• Ibuprofen is the recommended first‑line acute medication for pediatric migraine; it should be dosed according to body weight and taken at the earliest sign of headache. 84
• Ibuprofen is appropriate for mild‑to‑moderate attacks, while sumatriptan ODT is reserved for moderate‑to‑severe attacks or when ibuprofen fails after 2–3 episodes. 84

Preventive Therapy

• Initiating topiramate promptly is advised for adolescents who have experienced status migrainosus, as this indicates inadequate migraine control and a high risk of recurrent disabling attacks. 84
• Although topiramate is commonly used in clinical practice for pediatric migraine prevention, its efficacy has not been demonstrated in randomized controlled trials in children and adolescents (low‑quality evidence). 84
• Preventive therapy is indicated when a patient has ≥ 2 migraine attacks per month with disability lasting ≥ 3 days, or when acute medication use exceeds 2 days per week. 84
• If topiramate is contraindicated or poorly tolerated, propranolol may be used as an alternative first‑line preventive; amitriptyline is another option, especially when comorbid sleep disturbances or tension‑type headache are present. 84

Medication‑Overuse Prevention Counseling

• Patients and families should be educated that all acute migraine medications—including sumatriptan, ibuprofen, and ondansetron—must be limited to ≤ 2 days per week to prevent medication‑overuse headache. 84

Contraindicated Medications

• Opioids and butalbital‑containing compounds should never be prescribed for adolescent migraine because of questionable efficacy, high dependence risk, and propensity to cause rebound headaches. 84

Supportive Care and Family Involvement

• Successful clinical management of adolescent migraine requires active involvement of family members and school personnel to reinforce treatment adherence and lifestyle modifications. 84

Acute Migraine Treatment Recommendations

First‑Line Acute Therapy

• NSAIDs (e.g., ibuprofen 400‑800 mg, naproxen 500‑825 mg, aspirin 1000 mg) are the recommended initial treatment for mild‑to‑moderate migraine attacks, supported by high‑certainty evidence of efficacy. 85
• Acetaminophen 1000 mg is an alternative first‑line option when NSAIDs are contraindicated, but evidence indicates it is less effective than NSAIDs. 85

Triptan Therapy (Second‑Line)

• Oral triptans are indicated for moderate‑to‑severe attacks or when NSAIDs fail after 2–3 episodes; this recommendation is based on high‑certainty evidence. 85
• Tripan agents with strong evidence include sumatriptan 50‑100 mg, rizatriptan 10 mg, eletriptan 40 mg, naratriptan, and zolmitriptan 2.5‑5 mg. 85

Combination Therapy (Strongest Recommendation)

• Adding an NSAID (naproxen 500 mg) to a triptan (sumatriptan 50‑100 mg or rizatriptan 10 mg) is superior to either agent alone, providing 130 more patients per 1 000 with sustained pain relief at 48 h and 90 more patients per 1 000 with pain relief at 2 h; the number‑needed‑to‑treat is 3.5 for headache relief at 2 h. This is supported by high‑certainty evidence. 85
• A triptan + acetaminophen combination yields 300 more events per 1 000 patients achieving pain freedom at 2 h compared with acetaminophen alone. 85
• Initiating treatment early (when pain is mild) results in approximately 50 % of patients pain‑free at 2 h versus 28 % when treatment is delayed. 85

Third‑Line Acute Options

• CGRP antagonists (ubrogepant 50‑100 mg or rimegepant) are recommended only after failure of triptan‑NSAID combinations. 85
• Lasmiditan 50‑200 mg (a 5‑HT₁F receptor agonist) is an alternative for patients with cardiovascular contraindications to triptans; patients must avoid driving or operating machinery for at least 8 h after dosing. 85

Intravenous and Rescue Therapies

• Intravenous metoclopramide 10 mg provides analgesia through central dopamine antagonism and is effective for moderate‑to‑severe migraine with nausea. 85
• Intravenous ketorolac 30 mg has a rapid onset, an approximate 6‑hour duration, and carries minimal risk of rebound headache. 85
• Dihydroergotamine 0.5‑1.0 mg given intravenously or intranasally has good evidence for efficacy as monotherapy. 85

Medication‑Overuse Prevention

• All acute migraine medications—including NSAIDs, triptans, CGRP antagonists, ditans, and combination analgesics—should be limited to ≤2 days per week (≤10 days per month) to avoid medication‑overuse headache. 85
• When a patient requires acute treatment more than twice weekly, preventive therapy should be initiated immediately rather than increasing acute medication frequency. 85

Contraindicated Medications

• Opioids (e.g., hydrocodone, oxycodone, morphine, codeine, tramadol) and butalbital‑containing compounds are absolutely contraindicated for migraine because they have questionable efficacy, high dependence risk, and precipitate rebound headaches. This recommendation is based on high‑certainty evidence. 85

Dosing Summary (Reference 85)